• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Venus Concept Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/26/25 5:11:29 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email
    false0001409269NASDAQ00014092692025-06-252025-06-25

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     


    FORM 8-K
     


    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): June 25, 2025
     


    VENUS CONCEPT INC.
    (Exact name of registrant as specified in its charter)



    Delaware
    001-38238
    06-1681204
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification Number)
     
    235 Yorkland Blvd, Suite 900
    Toronto, Ontario M2J 4Y8
    (Address of principal executive offices, including Zip Code)
     
    Registrant’s telephone number, including area code: (877) 848-8430
     
    Not Applicable
    (Former name or former address, if changed since last report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, $0.0001 par value per share
     
    VERO
     
    The Nasdaq Capital Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



    Item 5.07.
    Submission of Matters to a Vote of Security Holders.

    On June 25, 2025, Venus Concept Inc. (the “Company”) held its Annual and Special Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the proposals listed below. The final voting results for such proposals are set forth in the following table. The proposal is described in detail in the Company’s definitive proxy statement for the Annual Meeting, as supplemented on June 12, 2025.

    1.          Election of Class II Directors:

    Nominee
    For
    Withheld
    Broker Non-Votes
    Louise Lacchin
    683,115
    5,175
    542,342
    Anthony Natale, M.D.
    680,224
    8,066
    542,342
    Stanley Tyler Hollmig, M.D.
    680,822
    7,468
    542,342

    2.          Ratification of the selection of MNP LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    For
    Against
    Abstain
    1,141,927
    87,720
    985

    3.          Approval of the issuance of up to 10,554,354 shares of common stock of the Company upon conversion of the 1,159,880 shares of Series Y Convertible Preferred Stock issued by the Company on May 24, 2024, September 26, 2024 and March 31, 2025.

    For
    Against
    Abstain
    Broker Non-Votes
    678,172
    9,064
    1,054
    542,342

    4.          Approval of the issuance of up to 271,819 shares of common stock of the Company upon conversion of the 298,997 shares of Series X Convertible Preferred Stock issued by the Company on October 4, 2023 and quarterly thereafter in satisfaction of accrued interest.

    For
    Against
    Abstain
    Broker Non-Votes
    489,263
    8,802
    979
    542,342

    5.          Approval of the issuance of up to 381,981 shares of common stock of the Company upon the conversion of the 1,575,810 shares of Senior Convertible Preferred Stock issued by the Company on May 15, 2023, July 12, 2023, September 8, 2023 and October 20, 2023.

    For
    Against
    Abstain
    Broker Non-Votes
    499,417
    9,073
    1,046
    542,342

    6.          Approval of the issuance of up to 64,454 shares of common stock of the Company upon the conversion of the Secured Subordinated Convertible Notes issued by the Company on March 31, 2025.

    For
    Against
    Abstain
    Broker Non-Votes
    677,737
    9,477
    1,076
    542,342


    Item 9.01.
    Financial Statements and Exhibits.

    Exhibit
    No.
     
    Description
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    VENUS CONCEPT INC.



    Date: June 26, 2025
    By:
     /s/ Domenic Della Penna


    Domenic Della Penna


    Chief Financial Officer



    Get the next $VERO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    SEC Filings

    View All

    SEC Form D filed by Venus Concept Inc.

    D - Venus Concept Inc. (0001409269) (Filer)

    4/9/26 5:06:19 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Venus Concept Inc.

    SCHEDULE 13D/A - Venus Concept Inc. (0001409269) (Subject)

    4/1/26 6:14:33 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Venus Concept Inc.

    EFFECT - Venus Concept Inc. (0001409269) (Filer)

    2/11/26 12:15:13 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger

    TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company"), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP ("Madryn") of a short-form merger transaction, pursuant to which 100% ownership of the Company's common stock is now consolidated under funds managed by Madryn (the "Short-form Merger"). The Short-form Merger was consummated on March 30, 2026, and the Company is now privately held by Madryn. All common shares outstanding prior to the Short-form Merger (other than shares held directly or indirectly by Madryn) have been converted, subject to appraisal rights, into

    4/1/26 9:02:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Announces Third Quarter 2025 Financial Results

    TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress: Energy Based Device ("EBD") revenues showing signs of stabilization. Total EBD systems sales of $9.6 million, up 2% year over year Total revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter. Primarily driven by a decline in the Hair Restoration business (the "Venus Hair Business") impacted by a delay in the pending sale. Third

    11/13/25 7:00:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments

    TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company"), a global leader in medical aesthetic technology, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market the Venus NOVA™, the Company's next-generation multi-application platform designed to redefine non-invasive treatments for the body, face, and skin. Venus NOVA integrates Adaptive Electrical Muscle Stimulation (EMS), proprietary (MP)² combining Multi-Polar Radio Frequency (RF) with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™ technology -delivering a powerful, comprehensive solution for body contouring, muscle co

    11/10/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    3/30/26 9:16:12 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Ew Healthcare Partners, L.P.

    4 - Venus Concept Inc. (0001409269) (Issuer)

    3/27/26 4:05:02 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    10/2/25 7:23:29 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    View All

    Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

    TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

    10/12/23 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

    TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

    10/11/22 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Ross J. Portaro as President of Global Sales

    TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

    10/12/21 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/8/24 7:51:38 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/3/24 7:59:41 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

    SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

    9/30/24 9:53:26 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Financials

    Live finance-specific insights

    View All

    Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

    TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (+1 201-389-0925 for international callers) and provide access code 13756285. A live webcast of the call will also be provided on the investor relations section of the Com

    10/1/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

    TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13754867. A live webcast of the call will also be provided on the investor relations section of the Company's

    7/16/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

    TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

    4/7/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care